A phase 3, multicenter, open-label extension study of oral Ozanimod for moderately to severely active Crohn’s disease.

  • Sparrow, Miles (Primary Chief Investigator (PCI))
  • McKenzie, Jo (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date2/02/22 → 31/12/25

Keywords

  • Gastroenterology
  • Crohn's disease
  • Clinical trial